Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted

Drug Metabolism and Disposition

Volumn 34, Issue 6, 2006, Pages 906-912

  Pitas, Grzegorz ^a   Laurenzana, Elizabeth M ^a   Williams, D Keith ^a   Owens, S Michael ^a   Gentry, W Brooks ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PHENYLCYCLIDINE; PHENCYCLIDINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BODY BURDEN; BOLUS INJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; LIQUID SCINTILLATION COUNTING; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; TESTIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BRAIN; BRAIN CHEMISTRY; HALLUCINOGENS; IMMUNIZATION, PASSIVE; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, INTRAVENOUS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; TESTIS;

ANIMALIA;

EID: 33646792942     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005934     Document Type: Article

References (20)

1. Bazin-Redureau MI, Renard CB, and Scherrmann JM (1997) Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49:277-281.
2. Briscoe RJ, Jeanville PM, Cabrera C, Baird TJ, Woods JH, and Landry DW (2001) A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and time course analysis. Int Immunopharmacol 1:1189-1198.
3. Burns RS and Lerner SE (1976) Perspectives: acute phencyclidine intoxication. Clin Toxicol 9:477-501.
4. Hardin JS, Wessinger WD, Proksch JW, and Owens SM (1998) Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 285:1113-1122.
5. Hardin JS, Wessinger WD, Wenger GR, Proksch JW, and Owens SM (2002) A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 302:119-126.
6. Harkness JE (1980) Chromodacryorrhea in laboratory rats (Rattus norvegicus): etiologic considerations. Lab Anim Sci 30:841-844.
7. Kosten TR and Kranzler HR (2004) What will we learn from the FDA clinical trials process and what will we still want to know about immunotherapies and depot medications to treat drug dependence? in New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions (Harwood HJ and Myers T.G. eds) pp 98-124, The National Academies Press, Washington, D.C.
8. Laurenzana EM, Gunnell MG, Gentry WB, and Owens SM (2003) Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther 306:1092-1098.
9. Malin D, Lake J, Lin A, Saldana M, Balch L, Irvin M, Chandrasekara H, Alvarado C, Hieda Y, Keyler D, et al. (2001) Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 68:87-92.
10. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G, Zhao K, Briscoe RJ, Almonte R, Woods JH, et al. (1998) A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95:10176-10181.
11. Pentel PR (2004) Vaccines and depot medications for drug addiction: rationale, mechanisms of action, and treatment implications, in New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions (Harwood HJ and Myers T.G. eds), pp 63-97, The National Academies Press, Washington, D.C.
12. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, et al. (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65:191-198.
13. Proksch JW, Gentry WB, and Owens SM (2000a) Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 292:831-837.
14. Proksch JW, Gentry WB, and Owens SM (2000b) The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis and serum. Drug Metab Dispos 28:742-747.
15. Roskos L, Davis C, and Schwab G (2004) The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 61:108-120.
16. Tuncok Y, Hieda Y, Keyler DE, Brown S, Ennifar S, Fattom A, and Pentel PR (2001) Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol 9:228-234.
17. Valentine JL, Arnold LW, and Owens SM (1994) Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther 269:1079-1085.
18. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, and Owens SM (1996) Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 278:709-716.
19. Valentine JL and Owens SM (1996) Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 278:717-724.
20. Wessinger WD and Owens SM (1991) Chronic administration of phencyclidine: pharmacokinetic comparison of intravenous and subcutaneous infusions in Sprague-Dawley rats. Drug Metab Dispos 19:719-721.